| Median (IQR) rate of moderate–severe exacerbations (composite of below*) | 1 (2) | 0 (2) | 1.21 (0.95 to 1.55) | 0.13 |
| No. (%) of patients hospitalised for asthma* | 15 (3.3) | 29 (6.4) | 0.52 (0.28 to 0.98) | 0.04 |
| No. (%) of patients attending A&E for asthma* | 29 (6.4) | 37 (8.2) | 0.73 (0.41 to 1.30) | 0.28 |
| No. (%) of patients attending out-of-hours for asthma* | 26 (5.7) | 32 (7.1) | 0.84 (0.46 to 1.51) | 0.56 |
| No. (%) of patients prescribed courses of oral prednisolone for exacerbations* | 247 (54.1) | 213 (46.9) | 1.24 (0.99 to 1.54) | 0.06 |
| No. (%) of patients prescribed nebulised short-acting β-agonists | 36 (7.9) | 63 (13.9) | 0.56 (0.37 to 0.84) | 0.005 |
| Median (IQR) no. inhaled short-acting β-agonists prescribed | 6 (10) | 7 (12) | 1.03 (0.89 to 1.19) | 0.70 |
| Median (IQR) dose of inhaled corticosteroids prescribed (μg/day) | 658 (1036) | 658 (1036) | 1.14 (1.00 to 1.30) | 0.04 |
| Median (IQR) no. inhaled long-acting β-agonists prescribed | 8 (9) | 6 (9) | 1.24 (1.08 to 1.42) | 0.003 |
| Median (IQR) no. primary care consultations for any reason | 9 (11) | 8 (11) | 1.08 (0.93 to 1.25) | 0.34 |
| No. (%) of patients who ‘did not attend’ primary care consultations for any reason | 81 (17.7) | 102 (22.5) | 0.53 (0.31 to 0.90) | 0.02 |